Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DYRK3 | O43781 | 4/20 | 0.56 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.46 |
| ▸ | PIM1 | P11309 | 1/20 | 0.46 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.46 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.46 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.46 |
| ▸ | CLK1 | P49759 | 1/20 | 0.46 |
| ▸ | CLK3 | P49761 | 1/20 | 0.46 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.46 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.46 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.46 |
| ▸ | HASPIN | Q8TF76 | 1/20 | 0.46 |
| ▸ | DYRK2 | Q92630 | 1/20 | 0.46 |
| ▸ | MYLK2 | Q9H1R3 | 1/20 | 0.46 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.46 |
| ▸ | STK17A | Q9UEE5 | 1/20 | 0.46 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 3/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2787378 | 1.00 | DYRK3 (0.56) | DYRK3PIK3CDPIM1CSNK2A2PIK3CA | |
| SCHEMBL4100843 | 0.93 | DYRK3 (0.57) | DYRK3PIK3CDPIM1CSNK2A2PIK3CA | |
| SCHEMBL4100838 | 0.93 | DYRK3 (0.57) | DYRK3PIK3CDPIM1CSNK2A2PIK3CA | |
| SCHEMBL2999201 | 0.89 | DYRK3 (0.50) | DYRK3PIK3CDPIM1CSNK2A2PIK3CA | |
| SCHEMBL2999196 | 0.89 | DYRK3 (0.50) | DYRK3PIK3CDPIM1CSNK2A2PIK3CA | |
| SCHEMBL2985121 | 0.88 | DYRK3 (0.46) | DYRK3PIK3CDPIM1CSNK2A2PIK3CA | |
| SCHEMBL2985118 | 0.88 | DYRK3 (0.46) | DYRK3PIK3CDPIM1CSNK2A2PIK3CA | |
| SCHEMBL2991252 | 0.88 | DYRK3 (0.46) | DYRK3PIK3CDPIM1CSNK2A2PIK3CA | |
| SCHEMBL2991249 | 0.88 | DYRK3 (0.46) | DYRK3PIK3CDPIM1CSNK2A2PIK3CA | |
| SCHEMBL5033042 | 0.88 | DYRK3 (0.46) | DYRK3PIK3CDPIM1CSNK2A2PIK3CA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7767701-B2 | protein serine/threonine kinase inhibitors such as 2-(2-Chloro-5-fluoro-phenylimino)-5-(2,3-dihydro-benzo[1-6]dioxin-6-ylmethylene)-thiazolidin-4-one, used for treating autoimmune diseases, HIV, cancer, anemia myelodysplastic syndrome and thrombocytopenia | GLAXOSMITHKLINE LLC (US) | 2010-08-03 | — | — | US | claimed |
| US-20090023742-A1 | THIAZOLONES FOR USE AS PI3 KINASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION | 2009-01-22 | — | — | US | claimed |
| EP-1993535-A2 | THIAZOLONES FOR USE AS PI3 KINASE INHIBITORS | SmithKline Beecham Corporation (US) | 2008-11-26 | — | — | EP | claimed |
| EP-1567112-B1 | THIAZOLIDIN-4-ONES FOR INHIBITING hYAK3 PROTEINS | SMITHKLINE BEECHAM CORP (US) | 2008-10-15 | — | — | EP | claimed |
| WO-2007103754-A2 | THIAZOLONES FOR USE AS PI3 KINASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2007-09-13 | — | — | WO | claimed |
| US-20060293338-A1 | Novel chemical compounds | GLAXOSMITHKLINE LLC | 2006-12-28 | — | — | US | claimed |
| US-7767701-B2 | protein serine/threonine kinase inhibitors such as 2-(2-Chloro-5-fluoro-phenylimino)-5-(2,3-dihydro-benzo[1-6]dioxin-6-ylmethylene)-thiazolidin-4-one, used for treating autoimmune diseases, HIV, cancer, anemia myelodysplastic syndrome and thrombocytopenia | GLAXOSMITHKLINE LLC (US) | 2010-08-03 | — | — | US | disclosed |
| US-20090203692-A1 | NOVEL CHEMICAL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION | 2009-08-13 | — | — | US | disclosed |
| US-20090023742-A1 | THIAZOLONES FOR USE AS PI3 KINASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION | 2009-01-22 | — | — | US | disclosed |
| EP-1993535-A2 | THIAZOLONES FOR USE AS PI3 KINASE INHIBITORS | SmithKline Beecham Corporation (US) | 2008-11-26 | — | — | EP | disclosed |
| EP-1567112-B1 | THIAZOLIDIN-4-ONES FOR INHIBITING hYAK3 PROTEINS | SMITHKLINE BEECHAM CORP (US) | 2008-10-15 | — | — | EP | disclosed |
| EP-1885362-A2 | NOVEL CHEMICAL COMPOUNDS | Smithkline Beecham Corporation (US) | 2008-02-13 | — | — | EP | disclosed |
| WO-2007103754-A2 | THIAZOLONES FOR USE AS PI3 KINASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2007-09-13 | — | — | WO | disclosed |
| US-20060293338-A1 | Novel chemical compounds | GLAXOSMITHKLINE LLC | 2006-12-28 | — | — | US | disclosed |
| WO-2006127458-A2 | NOVEL CHEMICAL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2006-11-30 | — | — | WO | disclosed |
| EP-1567112-A4 | NOVEL CHEMICAL COMPOUNDS | SMITHKLINE BEECHAM CORP (US) | 2006-11-15 | — | — | EP | disclosed |
| EP-1567112-A2 | NOVEL CHEMICAL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2005-08-31 | — | — | EP | disclosed |
| WO-2004047760-A2 | NOVEL CHEMICAL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2004-06-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060293338-A1 | Novel chemical compounds | HIPK3, HIPK1, HIPK4 | DYRK3 1446/4885PIK3CD 2145/4885PIM1 2267/4885 |
| US-20090023742-A1 | THIAZOLONES FOR USE AS PI3 KINASE INHIBITORS | PIK3CA, BTK, PI4KA | DYRK3 1357/4885PIK3CD 4/4885PIM1 169/4885 |
| US-20090203692-A1 | NOVEL CHEMICAL COMPOUNDS | HIPK3, HIPK1, HIPK4 | DYRK3 1471/4885PIK3CD 2485/4885PIM1 2800/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.